LC50 oral, rat; 1980 mg/kg MSDS.
LD50 Rabbit dermal 2250 mg/kg L2618.
2-Phenoxyethanol (PhE) has been shown to induce hepatotoxicity, renal toxicity, and hemolysis at dosages ? 400 mg/kg/day in subchronic and chronic studies in multiple species A32847.
The major hazards encountered in the use and handling of 2-phenoxyethanol stem from its toxicologic properties. Toxic by all routes (inhalation, ingestion, and dermal contact), exposure to this very faintly aromatic, colorless, oily liquid may occur from its use as a fixative for cosmetics, perfumes, and soaps; as a bactericide and insect repellant; as a solvent for cellulose acetate,dyes, stamp pad, ball point, and specialty inks; as a chemical intermediate for carboxylic acid esters (eg, acrylate, maleate) and polymers (eg, formaldehyde, melamine); and as a preservative for human specimens used for dissection and demonstrations in anatomical studies. Effects resulting from exposure to this substance can include eye irritation, headache, tremors, and central nervous system depression. If contact with the eyes occurs, irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes, and wash exposed skin thoroughly with soap and water. 2-Phenoxyethanol must be preheated before ignition can occur L2623.
Phenoxyethanol is a colorless liquid with a pleasant odor. It is a glycol ether used as a perfume fixative, insect repellent, antiseptic, solvent, preservative, and also as an anesthetic in fish aquaculture. Phenoxyethanol is an ether alcohol with aromatic properties. It is both naturally found and manufactured synthetically. Demonstrating antimicrobial ability, phenoxyethanol acts as an effective preservative in pharmaceuticals, cosmetics and lubricants L2619.
Phenoxyethanol (EU), or PE, is the most commonly used globally-approved preservative in personal care formulations. It is very easy to use in various types of formulations and is chemically stable. Phenoxyethanol is a colorless, clear, oily liquid with a faint aromatic odor at room temperature and a low water solubility and evaporation rate. It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) L2621.
According to the European Union Cosmetics Regulation (EC) n.1223/2009, phenoxyethanol is authorized as a preservative in cosmetic formulations at a maximum concentration of 1.0% L2625.
Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada L2623. It has also been used in vaccines and shown to inactivate bacteria, and several types of yeast A32838.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyclobenzaprine | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenoxyethanol. |
| Metoclopramide | The risk or severity of sedation can be increased when Metoclopramide is combined with Phenoxyethanol. |
| Lasmiditan | The risk or severity of adverse effects can be increased when Lasmiditan is combined with Phenoxyethanol. |
| Tramadol | The risk or severity of CNS depression can be increased when Phenoxyethanol is combined with Tramadol. |
| Ziprasidone | The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ziprasidone. |
| Haloperidol | The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenoxyethanol. |
| Fluoxetine | Phenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
| Oliceridine | The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Phenoxyethanol is combined with Oliceridine. |
| Ropeginterferon alfa-2b | The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Phenoxyethanol. |
| Daridorexant | The risk or severity of CNS depression can be increased when Phenoxyethanol is combined with Daridorexant. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Phenoxyethanol. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Phenoxyethanol. |
| Midazolam | The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Phenoxyethanol. |
| Ganaxolone | The risk or severity of sedation, somnolence, and CNS depression can be increased when Phenoxyethanol is combined with Ganaxolone. |
| Zuranolone | The risk or severity of CNS depression can be increased when Zuranolone is combined with Phenoxyethanol. |